Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269.

4CMenB Neisseria meningitidis meningococcal B vaccine meningococcal antigen typing system meningococcus serogroup B serum bactericidal antibody assay

Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
02 04 2020
Historique:
pubmed: 27 11 2019
medline: 22 6 2021
entrez: 27 11 2019
Statut: ppublish

Résumé

The Meningococcal Antigen Typing System (MATS) has been developed as an hSBA surrogate to evaluate potential coverage afforded by the 4-component meningococcal serogroup B vaccine (4CMenB:

Identifiants

pubmed: 31770063
doi: 10.1080/21645515.2019.1688039
pmc: PMC7227617
doi:

Substances chimiques

Antigens, Bacterial 0
Meningococcal Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

945-948

Références

Vaccine. 2013 Oct 9;31(43):4968-74
pubmed: 23954380
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19490-5
pubmed: 20962280
Clin Diagn Lab Immunol. 2005 Aug;12(8):970-6
pubmed: 16085915
Lancet. 2016 Dec 3;388(10061):2775-2782
pubmed: 28100432
Sci Rep. 2018 Feb 27;8(1):3700
pubmed: 29487324
Vaccine. 2011 Feb 24;29(10):1968-73
pubmed: 21241734
Lancet Infect Dis. 2017 Jul;17(7):754-762
pubmed: 28366725
J Exp Med. 1969 Jun 1;129(6):1327-48
pubmed: 4977281
J Exp Med. 1969 Jun 1;129(6):1307-26
pubmed: 4977280
Pediatr Infect Dis J. 2016 Apr;35(4):e113-23
pubmed: 26756390
Vaccine. 2016 May 17;34(23):2579-84
pubmed: 27083425
Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10834-9
pubmed: 16825336
Lancet. 2013 Mar 9;381(9869):825-35
pubmed: 23324563
Clin Vaccine Immunol. 2012 Oct;19(10):1609-17
pubmed: 22875603
JAMA. 2012 Feb 8;307(6):573-82
pubmed: 22318278

Auteurs

Maria Stella (M)

GSK, Siena, Italy.

Maria Giuliani (M)

GSK, Siena, Italy.

Alessia Biolchi (A)

GSK, Siena, Italy.

Sara Tomei (S)

GSK, Siena, Italy.

Rosita De Paola (R)

GSK, Siena, Italy.

Xilian Bai (X)

Meningococcal Reference Unit, Public Health England, Manchester, UK.

Ray Borrow (R)

Meningococcal Reference Unit, Public Health England, Manchester, UK.

Jay Lucidarme (J)

Meningococcal Reference Unit, Public Health England, Manchester, UK.

Rita La Gaetana (R)

GSK, Siena, Italy.

Mariagrazia Pizza (M)

GSK, Siena, Italy.

Laura Serino (L)

GSK, Siena, Italy.

Elena Mori (E)

GSK, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH